Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01992367
Recruitment Status : Completed
First Posted : November 25, 2013
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
Aslan Pharmaceuticals

Brief Summary:
This is a single-centre, placebo-controlled, randomised, double-blind study to evaluate the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of ASLAN003 in healthy subjects

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: ASLAN003 ACTIVE Phase 1

Detailed Description:

This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.

The study is divided into two parts:

  • Part A: SAD cohorts and 1 cohort to assess food effect of ASLAN003 PK.
  • Part B: MAD cohorts with one cohort being of healthy elderly subjects.

There will be a sentinel pair of subjects for each of SAD Cohorts 1, 2 and 3 who will be dosed first and then the same dose will be given to the rest of the subjects in the respective cohorts.

In addition, 8 subjects will receive ASLAN003 under both fed and fasted conditions

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects
Study Start Date : August 2013
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Arm Intervention/treatment
Placebo Comparator: Placebo
placebo arm
Drug: ASLAN003 ACTIVE
This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
Other Name: ASLAN 003 , LAS186323

ASLAN003
Active drug
Drug: ASLAN003 ACTIVE
This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
Other Name: ASLAN 003 , LAS186323




Primary Outcome Measures :
  1. Safety [ Time Frame: 6 months ]
    Safety assessments will include 12 lead ECGs, physical examiniation, vital signs measurements, pulse rate, RR, body temperature, clinical laboratory assessments and recording of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The inclusion criteria for all subjects are as follows:
  • are capable of understanding and complying with the requirements of the study and have signed the informed consent form (ICF);
  • are able to communicate well with the Investigator, and understand and comply with the requirements of the study;
  • male subjects aged between 21 and 50 years, inclusive (Part A and Cohorts 5, 6 and 7 of Part B only); male subjects and female subjects of non childbearing potential aged ≥55 years (Cohort 8 of Part B only);
  • body mass index (BMI) in the range of 18 to 30 kg/m2, inclusive;
  • healthy, as determined by pre study medical history, physical examinations, vital sign measurements, electrocardiogram (ECG; 12 lead reporting RR, PR, QRS, corrected QT [QTc] and QT interval corrected for heart rate using Fridericia's formulas [QTcF]) recordings with no evidence of clinically relevant medical disorders based on the opinion of the Investigator;
  • whose out-of-normal range clinical laboratory test results are not clinically relevant and are acceptable to the Investigator;
  • male subjects must be willing to use barrier contraception during sexual intercourse, i.e. condoms, even if their partners are post-menopausal, surgically sterile or are using accepted contraceptive methods, from the first day of dose administrations until 3 months after the last dose administration;

Exclusion Criteria:

  • The exclusion criteria for all subjects are as follows:
  • have participated in a study involving another investigational device or drug study within 90 days prior to randomisation in this study;
  • history of drug hypersensitivity reactions or hypersensitivity to drugs chemically related to the IP;
  • history or evidence of a clinically significant disorder, condition or disease (including, but not limited to, cardiopulmonary, oncologic, autoimmune, immunogenic, renal, metabolic, haematological or psychiatric), that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
  • existence of any surgical or medical condition which, in the judgement of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the IP;
  • clinically significant history or evidence of any active or suspected bacterial, viral, fungal or parasitic infection within the 30 days prior to randomisation (e.g. common cold, viral syndrome, flu-like symptoms, etc.);
  • active or recent history (within 30 days prior to randomisation) of acute viral infection of the skin (e.g. Herpes simplex, Molluscum contagiosum);
  • active or history of psoriasis, or a first-degree relative with active or history of psoriasis;
  • known history or evidence of active or latent tuberculosis infection (e.g. positive tuberculin skin test showing induration >5 mm or positive tuberculin blood test) in absence of previous Bacillus Calmette Guerin vaccination, or recent exposure (within 6 months prior to randomisation in this study) to an individual with active tuberculosis or with intention to travel to a country with a high risk of tuberculosis during the study period (including the follow up period);
  • history of autoimmune disease including but not limited to lupus, rheumatoid arthritis, autoimmune thyroid disease and immune thrombocytopenia;
  • with QT or QTcF values higher than 450 ms at screening;
  • history of regular alcohol consumption (within 6 months prior to randomisation in this study), defined as: an average weekly intake of greater than 21 units or any average daily intake of greater than 3 units. One unit is equivalent to a half pint (220 mL) of beer or 1 (25 mL) measure of spirits or 1 glass (125 mL) of wine;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01992367


Locations
Layout table for location information
Singapore
Singapore, Singapore
Sponsors and Collaborators
Aslan Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Please contact ASLAN Pharmaceuticals Pte Ltd contact@aslanpharma.com
Layout table for additonal information
Responsible Party: Aslan Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01992367    
Other Study ID Numbers: ASLAN003-001
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: October 2016